.jpg)
Present and Future of Drug Discovery and Development
BIOL-40378
Gain insight on the Present and Future of Drug Discovery and Development
This course explores the current state of drug discovery and development and the emerging trends and technologies that are shaping the future of the pharmaceutical industry. The course will cover emerging trends and technologies, such as artificial intelligence, genomics, and personalized medicine, and how these are changing the drug discovery and development landscape.
Present and Future of Drug Discovery and Development Course Introduction
Topics
- Introduction to the Present and Future of Drug Discovery and Development
- Emerging Technologies in Drug Research
- Precision Medicine and Pharmacogenomics
- Advancements in Immunotherapeutic and Gene Therapies
- Organ-on-a-chip and 3D Bioprinting
- Drug Repurposing and Combination Therapies
- Application of AI and Machine Learning
- Addressing Drug Resistance and Treatment Gaps
- Next Generation Cell Therapies for Regenerative Medicine
Learning Objectives
- Understand the current drug discovery and development process
- Understand emerging technologies used in drug discovery research
- Discuss recent immunotherapies
- Discuss recent cell and gene therapies
Prerequisites
There are no required prerequisites for this course. A bachelor’s degree in the life or physical sciences or more than ten years of biopharmaceutical industry, academic, or clinical experience with a secondary degree will help.
Format
This course is offered in an online asynchronous format. There are no set meeting times, however, students follow a weekly schedule and there will be deadlines to meet in terms of course requirements. This course cannot be completed at an accelerated rate.
Course Information
Course sessions
Section ID:
Class type:
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
No textbook required.
Policies:
- No refunds after: 9/15/2025
Schedule:
Instructor:
Kristen Taylor Meadows, Ph.D.
Dr. Taylor Meadows was part of the team that advanced ozanimod (Zeposia®) to FDA approval for Multiple Sclerosis and Ulcerative Colitis. Her work contributed to the understanding of its mechanism of action, differentiation, biomarker development, and indication expansion. In total, she has contributed to eight IND submissions and one NDA and supported multiple clinical-stage programs including a Phase III asset for Pulmonary Arterial Hypertension and Phase II programs in Crohn’s Disease, Ulcerative Colitis, and Asthma.
She has held senior leadership roles including Vice President of Discovery and Translational Science at Endpoint Health and Senior Director of Biology at Gossamer Bio, where she led the In Vivo Pharmacology Team that supported preclinical and clinical assets. Her areas of expertise include vitro assay development, in vivo pharmacology, translational science, and biomarker strategy.
Dr. Taylor Meadows is currently the Founder and Principal Consultant of KRTM Consulting Services, LLC, where she advises small and mid-sized biotech companies on discovery and early development strategy, including experimental design, platform development, and scientific positioning.
She holds a B.S. in Biochemistry from the University of Arizona, a Ph.D. in Biomedical Sciences from UC San Diego, and completed her postdoctoral training in Immunology at The Scripps Research Institute. Dr. Taylor Meadows is an active contributor to the scientific community through publications and conference presentations.